A new combination for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a combination of two experimental drugs for people with limited-stage small cell lung cancer that hasn't gotten worse after standard treatment with chemotherapy and radiation. The goal is to see if this combination can help control the cancer for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have limited-stage small cell lung cancer that hasn't spread and hasn't progressed after platinum-based chemo and radiation
- You are generally well enough to look after yourself (ECOG 0 or 1)
- Your doctor expects you to live at least 3 more months
- You have adequate bone marrow and organ function
- You have not had prior treatment with immune checkpoint inhibitors
- You do not have other cancers in the last 5 years, active autoimmune disease, or severe heart/blood vessel conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medication, HS-20093, to see if it can help people with limited-stage small cell lung cancer who have completed chemoradiation but cannot have surgery. The drug is given as an extra treatment after the standard therapy to try to prevent the cancer from coming back.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.